This announcement is a separate document:
科伦药业：关于子公司核心产品芦康沙妥珠单抗（sac-TMT）的新药申请获国家药品监督管理局受理的公告
Sichuan Kelun Pharmaceutical: Announcement Regarding the Acceptance of New Drug Application for Subsidiary's Core Pharmaceutical, Sac-TMT (Lukang Satuximab Monotherapy), by National Medical Products Administration.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.